Abstract 489
Background
To investigate the effects of non-steroidal aromatase inhibitors (NSAIs) on lipid metabolism and the correlation between NSAIs therapy and circulating tumor cells (CTCs) in postoperative patients with early-stage breast cancer.
Methods
We retrospectively analyzed 264 patients with early stage breast cancer (T1-3N0-3M0) in Guangdong General Hospital from 2009 to 2016. Patients with baseline lipid metabolism data were recruited in this study. The prevalence and number of CTCs were assessed using the CellSearch System at a mean time of 22.5 months after NSAIs therapy. Fasting blood was also drawn at the same time to assess lipid metabolism. We collected the clinical data, baseline metabolic-related data of all the recruited patients, and analyzed the lipid metabolism changes in patients received different NSAIs and the correlation between NSAIs therapy and CTC presence.
Results
We enrolled 90 patients with baseline lipid metabolism-related data, with an average follow-up of 22.5 months. There was no significant correlation between CTC presence and NSAIs therapy. However, LDL and Apolipoprotein B100 were significantly increased in letrozole group during follow-up (p = 0.004, p = 0.016). The levels of Apolipoprotein A1 in both anastrozole and letrozole groups were also significantly increased (p = 0.044, p = 0.034). No significant change was observed in the control group during follow-up.Table: 14P
Change in lipid indicators after 20 months of aromatase inhibitor therapy
| Anatrozole Group (n = 25) | Letrozole Group (n = 42) | No endocrine therapy (n = 23) | ||||
|---|---|---|---|---|---|---|
| LDL(mmol/l) | ||||||
| Baseline | 3.36±1.1 | 3.17±0.85 | 2.94±0.55 | |||
| Follow-up | 3.41±0.88 | 0.05 | 3.47±0.83 | 0.3* | 3.2±0.79 | 0.26 |
| TC(mmol/l) | ||||||
| Baseline | 5.53±0.99 | 5.24±1.18 | 5±0.74 | |||
| Follow-up | 5.43±0.93 | -0.1 | 5.47±1.2 | 0.23* | 5.32±0.98 | 0.32 |
| Apolipoprotein A1(g/l) | ||||||
| Baseline | 1.36±0.21 | 1.37±0.26 | 1.5±0.36 | |||
| Follow-up | 1.42±0.13 | 0.06* | 1.46±0.22 | 0.11* | 1.43±0.24 | -0.07 |
| Apolipoprotein B100(g/l) | ||||||
| Baseline | 1 | 0.9 | 0.89 | |||
| Follow-up | 1 | 0 | 1 | 0.1* | 0.9 | 0.01 |
Conclusions
There is no correlation between NSAIs therapy and CTC. Compared with anastrozole, letrozole has a more adverse long-term effect on lipid metabolism in patients.
Editorial acknowledgement
Clinical trial identification
The study was approved by the Institutional Review Board of Guangdong General Hospital (IRB NO. GDREC2012113H(R1)).
Legal entity responsible for the study
Guangdong General Hospital and Guangdong Academy of Medical Sciences.
Funding
The Special Fund of Development of Technology by Guangdong Province (No.2016A030313768), the National Natural Science Foundation of China (No. 81602645), the Science and Technology Project of Guangdong Province (No. 2012A03040001).
Disclosure
All authors have declared no conflicts of interest.